Biodesix Inc (BDSX) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $29.55 (+2.57%), Market cap $0.15B, 52-week low–high $0.25 ~ $19.40.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company pr
Financial statements, price targets, institutional (13F) holdings and related news for Biodesix Inc are updated in real time on BlackAll Trade.
Biodesix Inc trades at $29.55 (+2.57%). Real-time quotes and charts are available on BlackAll Trade.
Biodesix Inc has a market cap of about $0.15B.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to